Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Harvard Business School

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 072267

« Back to Dashboard

NDA 072267 describes FENOPROFEN CALCIUM, which is a drug marketed by Am Therap, Aurolife Pharma Llc, Halsey, Par Pharm, Quantum Pharmics, Warner Chilcott, Watson Labs, Actavis Elizabeth, Dava Pharms Inc, Ivax Sub Teva Pharms, Sun Pharm Industries, Usl Pharma, Watson Labs Teva, and Xspire Pharma, and is included in thirty NDAs. It is available from three suppliers. Additional details are available on the FENOPROFEN CALCIUM profile page.

The generic ingredient in FENOPROFEN CALCIUM is fenoprofen calcium. There are nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fenoprofen calcium profile page.
Summary for 072267
Applicant:Xspire Pharma
Ingredient:fenoprofen calcium
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 072267
Medical Subject Heading (MeSH) Categories for 072267
Suppliers and Packaging for NDA: 072267
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FENOPROFEN CALCIUM fenoprofen calcium TABLET;ORAL 072267 ANDA Mylan Pharmaceuticals Inc. 0378-0471 0378-0471-01 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-0471-01)
FENOPROFEN CALCIUM fenoprofen calcium TABLET;ORAL 072267 ANDA PD-Rx Pharmaceuticals, Inc. 55289-334 55289-334-30 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55289-334-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 600MG BASE
Approval Date:Aug 17, 1988TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Fish and Richardson
US Department of Justice
Harvard Business School
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.